AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|
26.9 C
New York
Tuesday, September 1, 2026

Tag: cell therapies

newssourceFORcompanyinformationcontent1releasesmarket

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET.

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss

Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist 
Rincell-1 addresses a multi $Bn global market opportunity  where no disease modifying treatments currently exist

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations

"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the...

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and Chief Executive Officer, Ryan Saadi, M.D., M.P.H., has personally contributed $500,000 towards the build-out and first-year operating costs of Tevogen’s new corporate headquarters in Warren, New Jersey.

Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®

Market Growth Driven by Rapid Disposable Technology Adoption, Expanding Biopharmaceutical Sector, and Government Support for Bioproduction REDDING, Calif., June 30, 2025 /PRNewswire/ --According to a...

Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®

Market Growth Driven by Rapid Disposable Technology Adoption, Expanding Biopharmaceutical Sector, and Government Support for Bioproduction REDDING, Calif., June 30, 2025 /PRNewswire/ --According to a...

AI Is Quietly Reinventing Healthcare–And Real Deployments Are Now Underway

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul...

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

Invetech and AiCella Announce Strategic Collaboration to Advance Cell Therapy Innovation

SAN DIEGO, June 27, 2025 /PRNewswire/ -- Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell therapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers